xFOREST Therapeutics is a Kyoto-based biotechnology company focused on RNA-targeted small molecule drug discovery. It uses its FOREST technology platform to analyze RNA structures and accelerate discovery of disease-specific RNA binders.
Pharmaceutical companies are increasingly partnering with biotechs developing RNA-targeting small molecules, driven by advances in RNA structural biology and the success of drugs like Roche's Evrysdi. The approach aims to address "undruggable" targets while offering oral availability advantages.
Drug discovery is expanding beyond traditional protein targets to include RNA-targeting small molecules, cell surface proteins, and sequence-based AI platforms capable of screening billions of candidates across the entire genome.
